产品
编 号：F623386
分子式：C15H20F3N5O3
分子量：375.35
分子式：C15H20F3N5O3
分子量：375.35
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1422365-94-3
产品详情
生物活性：
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model. Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors.
体内研究：
Lixumistat (acetate) does not affect metabolic regulation assessed by body weight, blood glucose, insulin levels and lipid metabolite content in mice with diet-induced obesity.Lixumistat (acetate) (50 mg/kg; for 2 months) does not affect body weight, general locomotion, or anxiety.Lixumistat (acetate) significantly attenuates the aging-induced decline in novel object recognition memory and spatial working memory.Lixumistat (acetate) significantly increases AMPK activation in the hippocampus of aged mice.Animal Model:C57BL/6J mice (young group/12-16 weeks, old groups/20-22 months)
Dosage:50 mg/kg
Administration:Oral administration (drinking water), for 2 months
Result:Attenuated age-related cognitive decline.
体外研究：
Lixumistat (acetate) (0.31-10 μM) phosphorylates AMPKα1 Thr172 in a dose- and time-dependent manner in NIH3T3 mouse fibroblast cells.Lixumistat (acetate) does not affect the expression of key factors involved in glucose homeostasis such as glucose-6-phosphatase (G6pase) or phosphoenolpyruvate carboxykinase 1 (Pck1).
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model. Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors.
体内研究：
Lixumistat (acetate) does not affect metabolic regulation assessed by body weight, blood glucose, insulin levels and lipid metabolite content in mice with diet-induced obesity.Lixumistat (acetate) (50 mg/kg; for 2 months) does not affect body weight, general locomotion, or anxiety.Lixumistat (acetate) significantly attenuates the aging-induced decline in novel object recognition memory and spatial working memory.Lixumistat (acetate) significantly increases AMPK activation in the hippocampus of aged mice.Animal Model:C57BL/6J mice (young group/12-16 weeks, old groups/20-22 months)
Dosage:50 mg/kg
Administration:Oral administration (drinking water), for 2 months
Result:Attenuated age-related cognitive decline.
体外研究：
Lixumistat (acetate) (0.31-10 μM) phosphorylates AMPKα1 Thr172 in a dose- and time-dependent manner in NIH3T3 mouse fibroblast cells.Lixumistat (acetate) does not affect the expression of key factors involved in glucose homeostasis such as glucose-6-phosphatase (G6pase) or phosphoenolpyruvate carboxykinase 1 (Pck1).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备